NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

AN2 Therapeutics, Inc. (ANTX) Stock Analysis

AN2 Therapeutics, Inc. (ANTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANTX

$3.60

+$0.04 (+1.12%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANTX with… →

ANTX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.58
Previous Close
$3.56
Day's Range
3.57–3.78
52-Week Range
1.00–7.19
Volume
177.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.98
Valuation
Market Cap
$135.85M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.05
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$35.17M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.74M
1-Year Return
+197.52%
Dividend and dates
Avg Volume
251.02K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANTX closed at $3.60, +197.52% over 1 year.

AN2 Therapeutics, Inc. (ANTX) has a market capitalization of $135.85M.

In fiscal 2025, ANTX reported revenue of $0.00.

ANTX Stock Return by Calendar Year

AN2 Therapeutics, Inc. (ANTX) return since Mar 2022: what $10,000 became

1 year
$10,000 $29,752
+197.52%
3 years
$10,000 $2,402
−75.98%
Since Mar 2022
$10,000 $2,338
−76.62%

If you had invested $10,000 in AN2 Therapeutics, Inc. (ANTX) at the close on March 25, 2022, the earliest close on record here, it would have been worth $2,338 at the close on October 21, 2026: −76.62% in total, −27.22% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+215.79%
2025−17.39%
2024−93.27%
2023+115.01%
2022 (partial year)−38.12%

As of October 21, 2026.

ANTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$35.17M—
2024$0.00−$51.32M—
2023$0.00−$64.73M—
2022$0.00−$40.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.11M−$35.17M—
2024$0.00—−$54.55M−$51.32M—
2023$0.00—−$69.64M−$64.73M—
2022$0.00—−$42.26M−$40.96M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AN2 Therapeutics, Inc. (ANTX) carries a market capitalisation of $135.85M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 21 employees.

Over the past 52 weeks the price has ranged from $1.00 to $7.19. The most recent close on file for ANTX is $3.60, dated October 21, 2026. That is +$0.04 (+1.12%) against the previous close. The latest close sits 260% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $35.17M. Trailing earnings per share are −1.05.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is −0.98. Annualized volatility over the trailing 4 years is 104.89%. Over the trailing twelve months the total return is +197.52%. Across 3 years the annualized return works out at −37.84%.

Growth & Income

The record shows no dividend for ANTX.

Across the complete calendar years on file, 2023 returned +115.01% and 2024 returned −93.27%. Of the 3 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +215.79% year to date.

Peer Comparison

AN2 Therapeutics, Inc. (ANTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AN2 Therapeutics, Inc. ANTX $135.85M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AN2 Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Visit website →